This trial is active, not recruiting.

Condition alimentary obesity
Sponsor Promomed, LLC
Start date November 2012
End date July 2015
Trial size 100000 participants
Trial identifier NCT01773733, PROMOMED-PRIMAVERA


The aim of this study is to summarize the data on efficacy and safety of Reduxine administration in the routine clinical practice according to the approved indications.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

weight reduction, kg
time frame: Dec 2015

Secondary Outcomes

Heart Rate, bpm
time frame: Dec 2015
Blood pressure, mmHg
time frame: Dec 2015
Adverse events
time frame: Dec 2015

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: - Men and women of 18-65 years of age to whom, in the doctor's opinion, the on-label use of Reduxine is indicated. - Patient's desire and ability to participate in the program and fulfill the doctor's instructions designed to achieve the treatment goal and the program requirements compliance. - Signed informed consent form for participation in the program. Exclusion Criteria: - Patients under age of 18 or older than 65; Current or the history of: - coronary artery disease (e.g. angina, myocardial infraction); - congestive heart failure; - tachycardia; - peripheral arterial occlusive disease; - arrythmia; - Uncontrolled arterial hypertension >145/90 mm Hg; - Hypersensitivity to sibutramine or any components of Reduxine®; - Current use of monoamineoxidase inhibitors (IMAO) or their use within the last 2 weeks; - Current use of other central acting weight reducing drugs or their use within the last 2 weeks; - Use on other drugs affecting the central nervous system (e.g. antidepressants, neuroleptics); tryptophan-containing drugs indicated for sleep disturbance; - Severe eating disorder (anorexia nervosa or bulimia); - Mental disease; - Gilles de la Tourette syndrome (generalized tics); - Body mass index ≤30 kg/m2 or ≤27 kg/m2 in the presence of concomitant diseases (dyslipidemia, diabetes); - Organic cause of obesity (e.g. hypothyrosis); - Thyrotoxicosis; - Sever liver and/or kidney function abnormality; - Benign prostatic hyperplasia; - Phaeochromocytoma; - Narrowangle glaucoma; - Documented pharmacologic, drug or alcohol addiction; - Pregnancy and lactation; - Refusal to sign the informed consent form for participation in the program; - Participation in a clinical study of any new drug product within 90 days prior to the screening visit.

Additional Information

Official title All-Russia Non-interventional Program of Reduxine Safety Monitoring for Weight Reduction in Patients With Alimentary Obesity in the Routine Clinical Practice
Description Secondary objectives: - to study the structure of the population of patients with the diet induced obesity with body mass index (BMI) 30 kg/m2 or diet induced obesity with BMI ≥27 kg/m2 associated with type 2 diabetes mellitus in respect of comorbidities and concomitant treatment to determine the areas for further investigations. - to introduce the elements of control of adverse cardiovascular risks into the routine clinical practice: questionnaire concerning enrollment criteria for Reduxine treatment initiation, algorithm of Reduxine administration and treatment efficacy and safety monitoring (assessment schedule). - to assess the effects of the treatment of overweight and obesity with Reduxine on patients' quality of life parameters. The Time Frame: the follow up of the study patients will be performed during six month to one year. Exception - premature discontinuation from the study. The scheduled visits of the patients to the investigational centres are: Week0 (inclusion of the patient), Week 2, 4, 6, 8, 10, 12, 16, 20, 24, 36 and Week 48.
Trial information was received from ClinicalTrials.gov and was last updated in August 2014.
Information provided to ClinicalTrials.gov by Promomed, LLC.